Search PubMed⌕ Search

Biomedical subjects

G Bounous

Publications and source records attributed to G Bounous.

75 records · Page 5Linked to original sources

[Use of elemental diet in intestinal lesions].

The recognition of potentially noxious physiological substances in the intestinal milieu, prompted the use of an "elemental" semi-hydrolysed formula diet in the prophylaxis of experimental acute ischemic enteropathy. An elemental diet protects the intestinal mucosa of rodents from radiation injury and facilitates mucosal healing. Clinical trials have shown the benefits of this form of treatment in the prevention of acute radiation enteritis and therapy of delayed enteropathy and Crohn's disease.

Acute Disease↗

The use of elemental diets during cancer therapy (review).

The intestinal mucosa depends upon luminal contents for part of its own supply of nutrients. Such nutrients are provided in a rapidly available state by elemental diets composed of chemically defined products containing nutrients in their simplest forms, e.g. amino acids, oligopeptides, essential fatty acids, triglycerides and simple sugars. These diets help to maintain the integrity of the intestinal mucosa under conditions such as abdominal irradiation and cancer chemotherapy which greatly impair the terminal digestion of nutrients in the intestinal brush border. The elemental diets also diminish the concentration of potentially injurious constituents of the intestinal juice, such as pancreatic proteases and bile salts, which play an important role in the intestinal complications of cancer therapy.

Animals↗

The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study.

Glutathione (GSH) concentration is high in most tumour cells and this may be an important factor in resistance to chemotherapy. Previous in-vitro and animal experiments have shown a differential response of tumour versus normal cells to various cysteine delivery systems. More specifically, an in-vitro assay showed that at concentrations that induce GSH synthesis in normal human cells, a specially prepared whey protein concentrate, Immunocal, caused GSH depletion and inhibition of proliferation in human breast cancer cells. On the basis of this information five patients with metastatic carcinoma of the breast, one of the pancreas and one of the liver were fed 30 grams of this whey protein concentrate daily for six months. In six patients the blood lymphocyte GSH levels were substantially above normal at the outset, reflecting high tumour GSH levels. Two patients (#1, #3) exhibited signs of tumour regression, normalization of haemoglobin and peripheral lymphocyte counts and a sustained drop of lymphocyte GSH levels towards normal. Two patients (#2, #7) showed stabilisation of the tumour, increased haemoglobin levels. In three patients (#4, #5, #6,) the disease progressed with a trend toward higher lymphocyte GSH levels. These results indicate that whey protein concentrate might deplete tumour cells of GSH and render them more vulnerable to chemotherapy.

Adenocarcinoma↗